Biblio
TCF4 promotes erythroid development. Exp Hematol. 2018.
Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. Blood. 2023.
. Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome. Ann Hematol. 2021.
. Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer J. 2022;12(12):166.
. Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression. Leukemia. 2023.
Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv. 2020;4(16):4029-4044.
Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells. Blood. 2020.
. Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry. Cytometry B Clin Cytom. 2022.
.